目的探讨神经内分泌瘤(NET)肝 转移患者多层螺旋CT(MSCT)表现及化疗栓 塞术(TACE)联合化疗治疗效果。方法 回 顾性分析我院2014年6月-2017年6月间收 治的162例NET肝转移患者临床资料，所 有患者均行MSCT检查，并根据治疗方案 分为观察组(n=90，化疗+TACE)和对照组 (n=72，化疗)。比较2组疗效并分析患者 治疗前后MSCT表现。结果 ①观察组总有 效率高于对照组(P<0.05)；②治疗前：CT 平扫表现为均匀或不均匀稍低密度，部分 患者病灶边界不清或部分病灶无法显示； 增强扫描对不同直径病灶表现不同，动脉 期和门脉期持续强化，门脉期以等密度强 化为主，延迟期病灶强化程度多低于肝实 质；③治疗后，治疗有效者表现为增强扫 描病灶较治疗前体积缩小，SD、PD者表现 为增强扫描病灶较治疗前无缩小或增大， 肿瘤边缘部分强化。结论 TACE联合化疗 治疗NET肝转移效果显著，MSCT在鉴别诊 断和指导NET肝转移方面有较多积极意 义。

Objective To explore the multi-slice spiral CT (MSCT) manifestations of patients with neuroendocrine neoplasia (NET) and liver metastases and the treatment effects of transcatheter arterial chemoembolization (TACE) combined with chemotherapy. Methods The clinical data of 162 cases of patients with NET and liver metastases in our hospital from June 2014 to June 2017 were retrospectively analyzed. All patients were given the MSCT and were divided into the observation group (n=90, chemotherapy and TACE) and the control group (n=72, chemotherapy). The efficacy of the two groups was compared, and the MSCT manifestations were analyzed before and after treatment. Results ① The total effective rate in the observation group was higher than that in the control group (P<0.05). ② Before treatment, CT plain scan showed there were uniform or non-uniform slightly low density, and some patients with unclear border lesions or some undisplayed lesions. Enhanced scan of different diameter lesions showed different manifestations, and continuous enhancement was in arterial phase and portal phase, and portal phase was mainly with equal density enhancement, and the enhancement degree of lesions in delayed phase was much lower than that in liver parenchyma. ③ After treatment, the volume of enhanced scan lesion in patients with effective treatment was smaller than that before treatment, and the volume in patients with SD and PD was not shrinked or increased compared with that before treatment but tumor edge was partial enhancement. Conclusion TACE combined with chemotherapy can have significant effects on NET liver metastasis, and MSCT has more positive significance in the differential diagnosis and guidance of NET liver metastasis.